MZT1P2

Across TCGA pan-cancer cohorts, MZT1P2 RNA differs between tumor and matched normal tissue in 10 of 18 cancer types tested, making tumor–normal expression one of MZT1P2’s most consistent transcriptional readouts.

The strongest signal is observed in kidney renal papillary cell carcinoma (KIRP), where MZT1P2 RNA is more highly expressed in tumor relative to normal tissue. In most cancer types MZT1P2 is over-expressed in tumor, although a few such as KICH and BRCA show the opposite, repressed pattern.

KIRP, KICH, and BLCA are the cancer types where MZT1P2 tumor–normal differential expression is most reproducible.

RNA tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in MZT1P2 RNA (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
KIRP	Male	All	+0.308	.009	6	view →
KICH	All	All	−0.298	<.001	5	view →
BLCA	All	All	+0.313	.005	4	view →
HNSC	Male	All	+0.135	.003	4	view →
BRCA	Female	All	−0.121	.010	4	view →
LIHC	All	All	+0.076	.007	3	view →
ESCA	All	II,III,IV	−0.255	<.001	2	view →
KIRC	All	All	+0.170	.002	2	view →
CHOL	All	All	+0.241	.016	1	view →
THCA	All	All	−0.206	.026	1	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 10 strongest of 10 lineages.

MZT1P2–KIRP

Open the KIRP breakdown →